High-Sensitivity Troponin T and NT-proBNP Kinetics in Breast Cancer Chemotherapy

Area of Science:

• Cardiology
• Oncology
• Biomarkers

Background:

• Doxorubicin (DOX) and trastuzumab (TRA) are chemotherapies linked to cardiac dysfunction.
• Monitoring cardiac biomarkers is crucial for patients undergoing these treatments.

Purpose of the Study:

• To investigate the impact of DOX and TRA on cardiac biomarkers, specifically high-sensitivity troponin T (hs-TnT) and N-terminal pro-brain natriuretic peptide (NT-proBNP).
• To assess the potential of hs-TnT in quantifying chemotherapy-induced myocardial injury.

Main Methods:

• Breast cancer patients received DOX or TRA therapy.
• hs-TnT and NT-proBNP were measured at baseline and on specific days during cycles 1 and 2.
• Statistical analysis was performed to compare biomarker levels between treatment groups and over time.

Main Results:

• DOX treatment was associated with significantly increased hs-TnT levels from baseline, between cycles, and peak levels.
• All DOX-treated patients showed detectable hs-TnT by day +1 of cycle 2, unlike TRA-treated patients.
• Both DOX and TRA caused transient increases in NT-proBNP post-treatment.

Conclusions:

• DOX significantly elevates hs-TnT, indicating cumulative myocardial injury.
• Both DOX and TRA acutely impact NT-proBNP levels.
• Serial hs-TnT measurements may quantify chemotherapy-related cardiac damage.